DEPIGMENTATION
effective active provided significantly more radiant, brighter and luminous skin complexion compared to baseline and placebo.
Skin homogeneity The percentage change in skin homogeneity (ΔEab*) after 28 days of treatment with tranexamic acid and placebo compared to baseline is shown in Figure 4. Study results demonstrate that tranexamic acid significantly decreased the contrast between pigmented skin and normal skin by 35% compared to baseline and by 15% compared to placebo, imparting a more even and homogeneous skin tone. The even skin tone is improved due to a more uniform pigmentation.
Red spots The percentage change in the number of red spots (facial vascular lesions) after 28 days of treatment with the tested products is demonstrated in Figure 5. A decrease in the number of the red spots indicates a more even skin appearance and a less red complexion. Study results demonstrate that tranexamic
acid reduced the number of red spots by 13% compared to baseline, and by 15% versus placebo, imparting a significantly more even skin tone and a less red complexion compared to baseline and placebo treatment.
Consumer self-assessment During the same clinical efficacy study, subjects were asked to evaluate their skin condition before and after 28 days of application of the tested products, and to compare against baseline. The percent of satisfied subjects after 28
days of use with tranexamic acid and placebo treatments is illustrated in Figure 6. Results confirmed that volunteers perceived visibly lighter pigmented spots on their face, a more even skin complexion and less dullness, while dark spots and blemishes were reduced after tranexamic acid application compared to baseline and placebo treatment. Digital pictures of a subject (age 62) at baseline and after 28 days of treatment with the tested products are shown in Figure 7. At baseline (Day 0) this subject showed
numerous dark spots/hyperpigmentation, an uneven skin tone, lack of radiance and numerous red spots on the face. Tranexamic acid treatment resulted in visibly lighter spots, a more even skin tone, enhanced skin radiance and reduced red areas compared to baseline (Day 0) and placebo skin sites. This subject’s individual results were 40%
more radiant skin, 33% less red spots and 19% lighter spot compared to baseline for a noticeably visible improvement overall. Digital pictures of another subject (age 63) at baseline and after 28 days of use with respective products are depicted in Figure 8. This volunteer’s individual results were 33%
less red spots and 31% brighter skin compared to baseline after 28 days of treatment with tranexamic acid. As is evident from the images, the skin looks noticeably more homogeneous, less red and more radiant after tranexamic acid treatment compared to baseline and placebo skin sites.
www.personalcaremagazine.com
Figure 8: Digital images of a subject (age 63) demonstrated that after 28 days of treatment, ViaDerm TXA imparted visibly less red complexion, more homogeneous skin tone and enhanced skin radiance compared to baseline (Day 0) and placebo skin sites
Conclusion ViaDerm® TXA (INCI: Tranexamic acid) delivers a multi-targeted biological activity with clinically proven multifunctional skin benefits to address various skin pigmentation conditions. Its mechanism of action impacts plasminogen/plasmin activity, which is involved in several biological pathways associated with melanogenesis. Also, it impacts vascular endothelial
growth factor activity associated with the angiogenesis process related to vascular pigmentation concerns. In vivo clinical efficacy study results confirm
that tranexamic acid visibly reduces dark spots/hyperpigmentation (UV spots, age spots, post inflammatory pigmentation), imparts a noticeably more even skin tone, enhances skin radiance and brightness, and reduces skin vascular conditions such as acne scars, acne lesions, post acne inflammation, erythema, rosacea, and spider veins after 28 days of use. This highly efficient and versatile active can
be incorporated in a variety of formulation types, and it is suitable in cosmetic applications designed for face, hands and body care.
References 1. Poojary S, Minni K. Tranexamic acid in melasma: A review. Journal of Pigmentary Disorders. 2015; 2; 12:1-4
2. Maeda K. Mechanism of action of topical tranexamic acid in the treatment of melasma and sun-induced skin hyperpigmentation. Cosmetics, MDPI. 2022. 9; 108:1-13
3. Ando H et al. Quasi-drugs developed in Japan for the prevention or treatment of hyperpigmentation disorders. International Journal Molecular Science. 2010. 11: 2566-2575
PC
4. Atefi N et al. Therapeutic effects of topical tranexamic acid in comparison with hydroquinone in treatment of women with melasma. Dermatological Therapy. 2017. 7: 417- 424
5. Kim K, Lim H. The uses of tranexamic acid in dermatology: a review. International Journal of Dermatology. 2022;1-10
6. Kaur A, Bhalla M. Topical tranexamic acid with microneedling in melasma. Acta Scientific Medical Sciences. 2019; 3; 4: 124- 126
7. Zhu JW et al. Tranexamic acid inhibits angiogenesis and melanogenesis in vitro by targeting VEGF receptors. International Journal of Medical Sciences. 2020; 17; 7: 903-911
8. Chardon A et al. Skin color typology and suntanning pathways. Int J
Cosmet.Sci. 1991;13; 4:191-208
9. Weatherall IL, Coombs BD. Skin color measurements in terms of CIELAB color space values. Journal of Investigative Dermatology. 1992; 99: 468-473
10. Ezerskaia et al. High sensitivity optical measurement of skin gloss. Biomedical Optics Express. 2017; 8; 9: 3981-3992
11. Fullerton A et al. Guidelines for measurement of skin color and erythema. Contact Dermatitis. 1996; 35; 1-10
12. Zawodny et al. VISIA skin analysis system as a tool to evaluate the reduction of pigmented skin and vascular lesions using the 532 nm laser. Clinical, Cosmetic and Investigational Dermatology. 2022; 15; 2187-2195
13. Goldsberry et al. VISIA system: A possible tool in the cosmetic practice. Journal of Drugs in Dermatology. 2014; 13; 11: 1312-1314
March 2024 PERSONAL CARE DAY 0 DAY 28
93
ViaDDerm TXA
PLACEBO
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112
